

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
	Yes, by the NICE technical team: NICE guideline NG241 states that the rate of familial ovarian cancer is higher in Ashkenazi Jewish ethnicity.
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
	Potential equality issue will be considered by committee
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
	Yes, draft scope has been updated to include Ashkenazi Jewish ethnicity
4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?



No

**Approved by Associate Director: Emily Crowe**

**Date: 24/04/2025**